GVK BIO, Asia's leading integrated research services provider and
Quantitative Solutions (QS), a leading modeling and simulation
consultancy to the pharmaceutical and biotech industry, have formed a
strategic alliance partnership to develop and market clinical trial
outcomes databases in high value disease areas.
* The databases capture summary level data for the clinical
safety and efficacy outcomes from publicly available data sources.
Models derived from them can be used to characterize the probability
distribution of clinical efficacy and tolerability as a function of
various treatment and patient factors.
* The databases can help companies conduct comparative efficacy
and safety analysis, link/scale biomarkers to clinical outcomes,
predict/improve trial outcome, and develop product differentiation
strategies.
* The databases are supported by customization and M&S
consulting services provided by GVK Bio and QS, respectively, to ensure
maximum flexibility and benefits to our clients
GVK BIO will distribute globally existing QS Databases in five
indications including Rheumatoid Arthritis & Psoriasis, Chronic HCV,
Neuropathic Pain, Osteoporosis (postmenopausal) and Major Depression
immediately. GVK BIO and QS plan to jointly develop and market
additional databases in Dyslipidemia, Schizophrenia, Alzheimer's, and
other indications shortly.
.
Best regards,
Sreeni
Sreeni Devidas Ph.D.
Vice President Business Development
GVK BioSciences
5457 Twin Knolls Road
Suite 101
Columbia, MD 21045
Tel: 443-838-6260
Fax: (703) 940 4088
www.gvkbio.com http://www.gvkbio.com/
Notice: The information contained in this electronic mail message is intended
only for the use of the designated recipient. This message is privileged and
confidential. and the property of GVK BIO or its affiliates and subsidiaries.
If the reader of this message is not the intended recipient or an agent
responsible for delivering it to the intended recipient, you are hereby
notified that you have received this message in error and that any review,
dissemination, distribution, or copying of this message is strictly prohibited.
If you have received this communication in error, please notify us immediately
by telephone +91-40-66929999 and destroy any and all copies of this message in
your possession (whether hard copies or electronically stored copies).